Choy H, Devore RF, Hande KR et al. A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non - small - cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study). Int J Radiat Oncol Biol Phys. 2000;47(4), 931-937.

Perez CA, Stanley K, Grundy G et al. Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non - oat cell carcinoma of the lung: report by the Radiation Therapy Oncology Group. Cancer. 1982;50(6), 1091-1099.

Perez CA, Bauer M, Edelstein S, Gillespie BW, Birch R. Impact of tumor control on survival in carcinoma of the lung treated with irradiation. Int J Radiat Oncol Biol Phys. 1986;12(4):539-47.

Droh J, Loeh E, Abbe B et al. Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer. Annals of internal medicine. 1990;113(1):1-8.

Tresser LC, Rheer A, Moser T et al. Significant effect of adjuvant chemotherapy on survival in locally advanced non - small - cell lung carcinoma. Journal of the National Cancer Institute. 1992;84(1):20-27

Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, Perry MC, Carey RW. A randomized trial of induction chemotherapy plus high - dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 1990;323(14):940-5.

Jeremic B, Shibamoto Y, Acimovic L et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol. 1996;14(4):1065-1070.

Belani C, Choy H, Bonomi P et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi - modality protocol. J Clin Oncol. 2005;23:5883-5891. .

Common Terminology Criteria for Adverse Events (CTCAE) | Protocol Development | CTEP. Accessed September

, 2020. https://ctep.cancer.gov/protocolDevelopment/ electronic_applications/ctc.htm#c tc_50. .

Lê Thu Hà. Đánh giá hiệu quả thuốc Erlotinib trong điều trị ung thư phổi biểu mô tuyến giai đoạn muộn, Luận án Tiến sỹ y học, Trường Đại học y Hà Nội. 2017.

Lê Tuấn Anh. Hóa xạ trị đồng thời ung thư phổi không tế bào nhỏ giai đoạn III, Luận án Tiến sỹ y học, Trường Đại học Y dược thành phố Hồ Chí Minh. 2015.

Choy H, Akerley W, Safran H, et al (1998). Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced nonsmall - cell lung cancer. J Clin Oncol. 2022;16:3316-3322. .

Yamamoto N, Nakagawa K, Nishimura Y, et al. Phase III study comparing second and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III nonsmall.cell lung cancer. J Clin Oncol. 2010;28(23):3739 - 3745. .

Bùi Công Toàn, Nguyễn Việt Long và cs. Đáp ứng điều trị và thời gian sống thêm của ung thư phổi không tế bào nhỏ giai đoạn III theo phác đồ hóa-xạ trị đồng thời. Nghiên cứu y học. 2012;15:162-168.

Huber RM, Flentje M, Schmidt M, et al. Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-small cell lung cancer: Study CTRT 99/97 by the Bronchial Carcinoma Therapy Group. J Clin Oncol.

;24:4397-4404.

Vokes EE, Herndon JE 2nd, Kelley MJ, et al. Induction followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non - small - cell lung. Annals of Oncology. 2007;3(2):25-30.

Belani CP, Lee JS, Socinski MA, et al. Randomized phase III trial comparing cisplatin - etoposide to carboplatin - paclitaxel in advanced or metastatic non small cell lung cancer. Annals of Oncology. 2005;4(16):1069 - 1075.